CoChat

Obesity--a neglected culprit in renal disease

Praga, M. · 2002 · Nephrology Dialysis Transplantation
Cited by 136

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Proteinuria is a recognized complication of morbid obesity, although it develops only in a minority of patients. Renal biopsies and autopsy studies have shown that focal and segmental glomerulosclerosis (FSG) is the commonest histologic lesion in proteinuric obese patients [1]. Obesity‐related FSG can be distinguished from idiopathic cases of FSG by glomerulomegaly and by less severe foot process effacement. From a clinical point of view, patients with obesity‐related glomerulopathies (ORG) do not develop the nephrotic syndrome (hypoalbuminaemia, oedema) even when there is massive and sustained proteinuria. This clinical characteristic (that is also observed in other renal diseases related to hyperfiltration such as reflux nephropathy or proteinuria related to renal mass reduction) is very useful to distinguish these patients from idiopathic FSG in which a complete nephrotic syndrome usually accompanies the presence of nephrotic‐range proteinuria [2]. The reasons why patients with ORG do not develop complete nephrotic syndrome remain unexplained but may relate to differences in the tubular management of filtered proteins and in a very slow proteinuria increase over the years which is characteristic of ORG and other hyperfiltering disorders. Initial descriptions of ORG suggested a relatively benign clinical course, based on the normal renal function of reported cases and very short periods of follow up. Recently, we have shown, however, that the long‐term prognosis of obese patients with biopsy‐proven FSG is poor with almost one‐half ultimately developing advanced renal failure [3]. These observations are of interest taking into account that a striking increase in the number of patients diagnosed with ORG in the last years has been reported recently. Thus, a retrospective analysis of all native renal biopsies received in the Renal Pathology Laboratory of Columbia University, New York (n=6818), revealed a progressive increase in biopsy incidence of ORG from 0.2% in 1986–2000 to 2% in 1996–2000 [1]. Studies in obese animals have shown an increased renal blood flow and glomerular filtration rate (GFR), mediated by vasodilation of the afferent arterioles [4]. The cause of these haemodynamic changes could be related to an increased salt reabsorption in the loop of Henle. The elevated salt reabsorption at a segment proximal to the macula densa would induce a rise in GFR through tubuloglomerular feedback, in addition to shifting the pressure natriuresis relationship to higher blood pressure values. The mechanisms responsible for this increased tubular reabsorption are still unclear but several experimental studies have shown that insulin resistance, increased sympathetic activity, and activated renin–angiotensin system (RAS), i.e. disturbances consistently found in obesity, could all play an important role. Studies in humans have confirmed these experimental results, showing an increase in renal plasma flow and GFR, together with increased transcapillary hydraulic pressure and filtration fraction in non‐diabetic, normotensive obese subjects in comparison with non‐obese [5]. Hyperlipidaemia is common in obese patients. Many experimental studies and some clinical data have shown that dyslipidaemia can contribute to renal injury, mainly through proliferation of mesangial cells and their extracellular matrix induced by LDL‐cholesterol. The obese Zucker rat is an experimental model of obesity, hyperinsulinaemia, and hyperlipidaemia that develops glomerulosclerosis and progressive renal failure. Treatment of hyperlipidaemia reduces glomerular injury in obese Zucker rats. Therefore, treatment with statins and other hypolipaemic agents may induce a beneficial effect in ORG, although no clinical studies have addressed this specific issue. Leptin, an adipocyte‐derived hormone, plays a critical role in the control of appetite and energy expenditure. Non‐diabetic obese subjects as well as obese type 2 diabetic patients exhibit high serum leptin levels. Mutations in the Ob‐Rb leptin receptor in the db/db mouse lead to leptin resistance, hyperleptinaemia, obesity, and type 2 diabetes with glomerulosclerosis. Recent studies [6] have shown that leptin stimulates cellular proliferation and expression of the prosclerotic cytokine TGF‐β1 cytokine. Chronic leptin infusion into normal rats induced proteinuria and focal glomerulosclerosis accompanied by elevated glomerular TGF‐β1 and type IV collagen expression. These studies suggest that leptin could play an important role in the pathogenesis of glomerulosclerosis associated with obesity. Other recent studies have provided exciting data about the active role of adipocytes in the hormonal regulation of energy balance. Resistin, another hormone secreted by adipocytes, appears to be crucial in the insulin resistance linked to obesity and type 2 diabetes [7]. Serum levels of resistin are increased markedly in obese experimental animals and are decreased by thiazolidinendiones, drugs curren

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/17.7.1157

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 136

Metadata

Authors
Praga, M.
Venue
Nephrology Dialysis Transplantation
Published
2002-07-01
Volume
17
Issue
7
Pages
1157-1159
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2098100684
Cited by
136
References
1
FWCI
3.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.